These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17201939)

  • 1. The challenge of overactive bladder therapy: alternative to antimuscarinic agents.
    Lazzeri M; Spinelli M
    Int Braz J Urol; 2006; 32(6):620-30. PubMed ID: 17201939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing overactive bladder.
    Robinson D; Cardozo L
    Climacteric; 2019 Jun; 22(3):250-256. PubMed ID: 31034265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.
    Araklitis G; Robinson D; Cardozo L
    Clin Interv Aging; 2020; 15():1493-1503. PubMed ID: 32921995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactive bladder - 18 years - Part II.
    Truzzi JC; Gomes CM; Bezerra CA; Plata IM; Campos J; Garrido GL; Almeida FG; Averbeck MA; Fornari A; Salazar A; Dell'Oro A; Cintra C; Sacomani CA; Tapia JP; Brambila E; Longo EM; Rocha FT; Coutinho F; Favre G; Garcia JA; Castano J; Reyes M; Leyton RE; Ferreira RS; Duran S; Lopez V; Reges R
    Int Braz J Urol; 2016; 42(2):199-214. PubMed ID: 27176185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Overactive Bladder Therapeutic Options.
    Babin CP; Catalano NT; Yancey DM; Pearl NZ; Koonce EM; Ahmadzadeh S; Shekoohi S; Cornett EM; Kaye AD
    Am J Ther; 2024 Jul-Aug 01; 31(4):e410-e419. PubMed ID: 37171410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Overactive Bladder Symptoms After Radical Prostatectomy.
    Peyronnet B; Brucker BM
    Curr Urol Rep; 2018 Oct; 19(12):95. PubMed ID: 30306278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in managing overactive bladder.
    Araklitis G; Baines G; da Silva AS; Robinson D; Cardozo L
    F1000Res; 2020; 9():. PubMed ID: 32968482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature.
    Kasman A; Stave C; Elliott CS
    Neurourol Urodyn; 2019 Nov; 38(8):2083-2092. PubMed ID: 31483070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments.
    Staskin D
    Expert Opin Pharmacother; 2022 Sep; 23(13):1475-1477. PubMed ID: 36045592
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical pharmacology of the medical treatment for overactive bladder in adults.
    Mostafaei H; Shariat SF; Salehi-Pourmehr H; Janisch F; Mori K; Quhal F; Hajebrahimi S
    Expert Rev Clin Pharmacol; 2020 Jul; 13(7):707-720. PubMed ID: 32500759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and Treatment of Overactive Bladder in Women.
    Raju R; Linder BJ
    Mayo Clin Proc; 2020 Feb; 95(2):370-377. PubMed ID: 32029089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment.
    Hartigan SM; Dmochowski RR
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):103-110. PubMed ID: 31918590
    [No Abstract]   [Full Text] [Related]  

  • 17. Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome.
    Xia L; Yan H; Sun Y; Zhu Y; Wu Y; Chen Z; Su S
    Medicine (Baltimore); 2021 Nov; 100(45):e27745. PubMed ID: 34766587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB).
    El-Zawahry A
    Curr Urol Rep; 2019 May; 20(6):33. PubMed ID: 31098731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.
    Ganguly A; Tyagi S; Chermansky C; Kanai A; Beckel J; Hashimoto M; Cho KJ; Chancellor M; Kaufman J; Yoshimura N; Tyagi P
    Drugs Aging; 2023 Mar; 40(3):241-261. PubMed ID: 36879156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Treatment of Overactive Bladder.
    Loloi J; Clearwater W; Schulz A; Suadicani SO; Abraham N
    Urol Clin North Am; 2022 May; 49(2):249-261. PubMed ID: 35428431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.